TTRX (Turn Therapeutics) Net Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TTRX Turn Therapeutics Inc TTRX
11 GF Score
Price $8.25
View Full Analysis

What is Turn Therapeutics Net Margin %?

Turn Therapeutics TTRX +10.89% 11 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates TTRX with a GF Score™ of 11/100. Among 943 Biotechnology companies, Turn Therapeutics ranks worse than 106044.43% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Turn Therapeutics's Net Income for the three months ended in Mar. 2026 was $-0.97 Mil. Turn Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Turn Therapeutics's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Turn Therapeutics's Net Margin % or its related term are showing as below:


TTRX's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.56
* Ranked among companies with meaningful Net Margin % only.

Turn Therapeutics  (NAS:TTRX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Turn Therapeutics Net Margin % Related Terms

Turn Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Turn Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Turn Therapeutics Net Margin % Chart

Turn Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Net Margin %
0.00 0.00 0.00

Turn Therapeutics Quarterly Data
Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

TTRX vs IRD, VRXA, IFRX: Net Margin % Comparison

For the Biotechnology subindustry, Turn Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Turn Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Turn Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Turn Therapeutics's Net Margin % falls into.


TTRX
11GF Score
Turn Therapeutics Inc TTRX
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Turn Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Turn Therapeutics's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-3.194/0
= %

Turn Therapeutics's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.971/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Turn Therapeutics (TTRX) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Turn Therapeutics and its competitors. According to the industry distribution chart, Turn Therapeutics ranks #999999 out of 943 companies in the Biotechnology industry.
Is Turn Therapeutics' Net Margin % too high?
Turn Therapeutics' current Net Margin % is 0.00%. Based on the distribution chart, Turn Therapeutics ranks #999999 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Turn Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Turn Therapeutics' Net Margin % compare to IRD and VRXA?
According to the Biotechnology industry distribution chart, Turn Therapeutics ranks #999999 out of 943 companies for Net Margin %. This places Turn Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Turn Therapeutics and its competitors. Turn Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Turn Therapeutics stock overvalued right now?
Turn Therapeutics (TTRX) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Turn Therapeutics' overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Turn Therapeutics (TTRX), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Turn Therapeutics Business Description

Address 250 North Westlake Boulevard, Suite 210, Westlake Village, CA, USA, 91362
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
11GF Score

Get the complete analysis for TTRX

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.25
Price